Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › ATTR-CM

ATTR-CM

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for ATTR-CM

2 trials tracked for ATTR-CM: 1 in phase 3 or 4.

2Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Other / NA 1
  1. Phase 3 Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy Completed
  2. N/A A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF). Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
Cardiology Meta-analysis
SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy Could a common diabetes drug help people with a serious heart condition live longer?
A meta-analysis of 7 observational studies including 7,283 patients with ATTR cardiomyopathy found SGLT2 inhibitor use was associated with l…
A common diabetes drug linked to lower death risk and fewer heart attacks for people with a serious heart condition called transthyretin amy…
Apr 2, 2026